Agreed, there is no consensus that "closed generics", however defined, should be banned. It is certain that the Board did not ban them, nor could they. [image: Logo] Mike Rodenbaugh address: 548 Market Street, Box 55819 San Francisco, CA 94104 email: mike@rodenbaugh.com phone: +1 (415) 738-8087 On Mon, Jun 29, 2020 at 2:44 PM Marc Trachtenberg via Gnso-newgtld-wg < gnso-newgtld-wg@icann.org> wrote:
+1 to Paul. Everyone does not agree with that position.
*Marc H. Trachtenberg* Shareholder Greenberg Traurig, LLP | 77 West Wacker Drive | Suite 3100 | Chicago, IL 60601 Tel 312.456.1020
Mobile 773.677.3305
trac@gtlaw.com | www.gtlaw.com
[image: Greenberg Traurig]
*From:* Gnso-newgtld-wg [mailto:gnso-newgtld-wg-bounces@icann.org] *On Behalf Of *McGrady, Paul D. *Sent:* Monday, June 29, 2020 4:41 PM *To:* Jeff Neuman <jeff.neuman@comlaude.com>; Cheryl Langdon-Orr < langdonorr@gmail.com> *Cc:* gnso-newgtld-wg@icann.org *Subject:* [Gnso-newgtld-wg] Package 6
**EXTERNAL TO GT**
Hi Jeff & Cheryl,
I was under the impression that we were going to discuss Closed Generics again, but I see it is Package 6. Is Closed Generics not on the agenda for upcoming calls? If it is, how can we be doing the so-called “Can’t live with” exercise when the topic isn’t closed on the calls?
Also, I see that the text indicates that the WG agrees the Board instituted a ban on them in the last round. That is not what the Board resolution says – and in fact there was much discussion on the calls and chat about how “ban” does not apply. There were three options: (1) make a change to non-exclusive access, (2) maintain & defer to the next round, or (3) withdraw. Is there a way to make that section reflect the actual facts before we have to undertake the so-called “can’t live with” exercise? The way it is written now essentially takes the starting position of the part of the WG that wants to censor closed generics and implies everyone agrees with it. That isn’t the case.
Best,
Paul
*Taft * */ * *Paul* *D. McGrady* / Partner Taft Stettinius & Hollister LLP 111 E. Wacker Drive, Suite 2800 Chicago, Illinois 60601-3713 Tel: 312.527.4000 • Fax: 312.754.2354 Direct: 312.836.4094 • Cell: 312.882.5020 *www.taftlaw.com <https://urldefense.com/v3/__http:/www.taftlaw.com__;!!DUT_TFPxUQ!WfZ003NwR5M...> * / PMcGrady@taftlaw.com
[image: https://dg01.redatatech.com/onprem_image_fetch?cid=1016&ep=2b8abf60503911b86...]
[image: V-Card Icon]
Subscribe to our law updates <https://urldefense.com/v3/__http:/taftlaw.com/news/subscribe__;!!DUT_TFPxUQ!...>
To receive regular COVID-19 updates from Taft, subscribe here <https://urldefense.com/v3/__https:/www.taftlaw.com/general/subscribe__;!!DUT...>. For additional resources, visit Taft's COVID-19 Resource Toolkit <https://urldefense.com/v3/__https:/www.taftlaw.com/general/coronavirus-covid...> .
This message may contain information that is attorney-client privileged, attorney work product or otherwise confidential. If you are not an intended recipient, use and disclosure of this message are prohibited. If you received this transmission in error, please notify the sender by reply e-mail and delete the message and any attachments.
------------------------------ If you are not an intended recipient of confidential and privileged information in this email, please delete it, notify us immediately at postmaster@gtlaw.com, and do not use or disseminate the information. _______________________________________________ Gnso-newgtld-wg mailing list Gnso-newgtld-wg@icann.org https://mm.icann.org/mailman/listinfo/gnso-newgtld-wg _______________________________________________ By submitting your personal data, you consent to the processing of your personal data for purposes of subscribing to this mailing list accordance with the ICANN Privacy Policy (https://www.icann.org/privacy/policy) and the website Terms of Service (https://www.icann.org/privacy/tos). You can visit the Mailman link above to change your membership status or configuration, including unsubscribing, setting digest-style delivery or disabling delivery altogether (e.g., for a vacation), and so on.
